card asc Search Results


96
Proteintech card asc monoclonal antibody
Card Asc Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/ASC%2FTMS1+Antibody/pm41904987-47-162-168
Average 96 stars, based on 1 article reviews
card asc monoclonal antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
MedChemExpress human asc protein
Human Asc Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/PYCARD%2C+Human/10__1016_slash_j__eng__2025__07__039-129-27-31
Average 94 stars, based on 1 article reviews
human asc protein - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
ABclonal Biotechnology anti asc antibody
Anti Asc Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/ASC+%2F+TMS1+Rabbit+pAb/pm34603335-201-16-25
Average 96 stars, based on 1 article reviews
anti asc antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
MedChemExpress asc
MB inhibits pyroptosis in AMs caused <t>by</t> <t>NLRP3</t> inflammasome in HCA rats. (A) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (B–F) Western blot bands and relative expression levels of NLRP3, caspase-1, pro-caspase-1, <t>ASC,</t> GSDMD-N, and GSDMD in AMs. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin-D.
Asc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/TMS1%2FASC+Antibody/pmc12450078-132-63-68
Average 94 stars, based on 1 article reviews
asc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Boster Bio anti asc
MB inhibits pyroptosis in AMs caused <t>by</t> <t>NLRP3</t> inflammasome in HCA rats. (A) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (B–F) Western blot bands and relative expression levels of NLRP3, caspase-1, pro-caspase-1, <t>ASC,</t> GSDMD-N, and GSDMD in AMs. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin-D.
Anti Asc, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/Anti-ASC+PYCARD+Antibody/pmc12978002-89-28-30
Average 93 stars, based on 1 article reviews
anti asc - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Rockland Immunochemicals rabbit polyclonal anti card
MB inhibits pyroptosis in AMs caused <t>by</t> <t>NLRP3</t> inflammasome in HCA rats. (A) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (B–F) Western blot bands and relative expression levels of NLRP3, caspase-1, pro-caspase-1, <t>ASC,</t> GSDMD-N, and GSDMD in AMs. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin-D.
Rabbit Polyclonal Anti Card, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/ASC+Antibody/10__7554_slash_elife__65351-422-19-18
Average 94 stars, based on 1 article reviews
rabbit polyclonal anti card - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

91
Cusabio elisa kit
MB inhibits pyroptosis in AMs caused <t>by</t> <t>NLRP3</t> inflammasome in HCA rats. (A) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (B–F) Western blot bands and relative expression levels of NLRP3, caspase-1, pro-caspase-1, <t>ASC,</t> GSDMD-N, and GSDMD in AMs. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin-D.
Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/Mouse+Apoptosis-associated+speck-like+protein+containing+a+CARD(PYCARD)+ELISA+kit/10__1097_slash_mao__0000000000002537-54-72-74
Average 91 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

90
ProSci Incorporated anti asc polyclonal
FIG. 4. Cryopyrin requires oligomerization for ASC binding and IL-1 secretion. A, schematic representation of the cryopyrinPD-Fpk3 or Fpk3 vector. B, 1 108 THP-1 cryopyrinPD-Fpk3 and Fpk3 stable cells were immunoprecipitated (IP) with <t>polyclonal</t> myc Ab (top panel), and total lysates (bottom panel) from stable cells were immunoblotted with monoclonal ASC Ab. C, 0.5 106 THP-1 cells stably expressing with cryopyrinPD-Fpk3 or Fpk3 vector in the presence () or absence () of Fpk3 ligand AP1510 for 0, 4, and 8 h followed by detection of IL-1 secretion. The results are given as the mean S.D. of triplicate cultures.
Anti Asc Polyclonal, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/ASC+Antibody/10__1074_slash_jbc__m401178200-81-16-19
Average 90 stars, based on 1 article reviews
anti asc polyclonal - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

92
Cusabio human asc
Figure 3. Monocytes from CMML KRASmut patients present a constitutive inflammasome activation (A) Percentage of <t>ASC-specking</t> monocytes in healthy controls (white bars), CMML patients without KRAS mutation (KRASwt, blue bars), and CMML patients with a KRAS mutation (KRASmut, orange bars) at baseline or treated as indicated for NLRP3 (LPS+ATP) or pyrin (LPS+TcdB) inflammasome activation. (B and C) Release of IL-1b from peripheral blood mononuclear cells (PBMCs) (B) and the formation of ASC specks in monocytes (C) in CMML KRASmut patients at baseline or after the indicated stimulation or treatment (LPS+ATP and LPS+TcdB for NLRP3 or pyrin inflammasome, respectively), in the absence/presence of MCC950. (B) Fold increase was calculated to control non-stimulated conditions, where the average of the higher value used to calculate fold increase is 1,066.58 pg/mL. (D) Percentage of extracellular LDH from untreated PBMCs from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). Data are normalized to the percentage of monocytes. (E) Plasma concentration of HMGB1 <t>and</t> <t>P2X7</t> receptor from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). For (A)–(E), data are represented as mean ± SEM; each dot represents an individual patient; ordinary one-way ANOVA test (two-tailed) was used for (A) (* compares CMML KRASmut vs. healthy controls; y compares CMML KRASmut vs. CMML KRASwt), and two-tailed t test in (B)–(E). Note that * or yp < 0.05; **p < 0.01; ***p < 0.001; **** or yyyyp < 0.0001; ns, no significant difference (p > 0.05).
Human Asc, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/Human+Apoptosis-associated+speck-like+protein+containing+a+CARD(PYCARD)+ELISA+kit/pm38118408-177-43-46
Average 92 stars, based on 1 article reviews
human asc - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
MedChemExpress anti atgl rabbit
Figure 3. Monocytes from CMML KRASmut patients present a constitutive inflammasome activation (A) Percentage of <t>ASC-specking</t> monocytes in healthy controls (white bars), CMML patients without KRAS mutation (KRASwt, blue bars), and CMML patients with a KRAS mutation (KRASmut, orange bars) at baseline or treated as indicated for NLRP3 (LPS+ATP) or pyrin (LPS+TcdB) inflammasome activation. (B and C) Release of IL-1b from peripheral blood mononuclear cells (PBMCs) (B) and the formation of ASC specks in monocytes (C) in CMML KRASmut patients at baseline or after the indicated stimulation or treatment (LPS+ATP and LPS+TcdB for NLRP3 or pyrin inflammasome, respectively), in the absence/presence of MCC950. (B) Fold increase was calculated to control non-stimulated conditions, where the average of the higher value used to calculate fold increase is 1,066.58 pg/mL. (D) Percentage of extracellular LDH from untreated PBMCs from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). Data are normalized to the percentage of monocytes. (E) Plasma concentration of HMGB1 <t>and</t> <t>P2X7</t> receptor from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). For (A)–(E), data are represented as mean ± SEM; each dot represents an individual patient; ordinary one-way ANOVA test (two-tailed) was used for (A) (* compares CMML KRASmut vs. healthy controls; y compares CMML KRASmut vs. CMML KRASwt), and two-tailed t test in (B)–(E). Note that * or yp < 0.05; **p < 0.01; ***p < 0.001; **** or yyyyp < 0.0001; ns, no significant difference (p > 0.05).
Anti Atgl Rabbit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/TMS1%2FASC+Antibody/10__1016_slash_j__jtcme__2025__12__001-81-9-12
Average 93 stars, based on 1 article reviews
anti atgl rabbit - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene pycard v1
Figure 3. Monocytes from CMML KRASmut patients present a constitutive inflammasome activation (A) Percentage of <t>ASC-specking</t> monocytes in healthy controls (white bars), CMML patients without KRAS mutation (KRASwt, blue bars), and CMML patients with a KRAS mutation (KRASmut, orange bars) at baseline or treated as indicated for NLRP3 (LPS+ATP) or pyrin (LPS+TcdB) inflammasome activation. (B and C) Release of IL-1b from peripheral blood mononuclear cells (PBMCs) (B) and the formation of ASC specks in monocytes (C) in CMML KRASmut patients at baseline or after the indicated stimulation or treatment (LPS+ATP and LPS+TcdB for NLRP3 or pyrin inflammasome, respectively), in the absence/presence of MCC950. (B) Fold increase was calculated to control non-stimulated conditions, where the average of the higher value used to calculate fold increase is 1,066.58 pg/mL. (D) Percentage of extracellular LDH from untreated PBMCs from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). Data are normalized to the percentage of monocytes. (E) Plasma concentration of HMGB1 <t>and</t> <t>P2X7</t> receptor from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). For (A)–(E), data are represented as mean ± SEM; each dot represents an individual patient; ordinary one-way ANOVA test (two-tailed) was used for (A) (* compares CMML KRASmut vs. healthy controls; y compares CMML KRASmut vs. CMML KRASwt), and two-tailed t test in (B)–(E). Note that * or yp < 0.05; **p < 0.01; ***p < 0.001; **** or yyyyp < 0.0001; ns, no significant difference (p > 0.05).
Pycard V1, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/TMS1+(PYCARD)+(NM_145183)+Human+Untagged+Clone/pm22008067-139-7-9
Average 90 stars, based on 1 article reviews
pycard v1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai Korain Biotech Co Ltd apoptosis elisa kit
Figure 3. Monocytes from CMML KRASmut patients present a constitutive inflammasome activation (A) Percentage of <t>ASC-specking</t> monocytes in healthy controls (white bars), CMML patients without KRAS mutation (KRASwt, blue bars), and CMML patients with a KRAS mutation (KRASmut, orange bars) at baseline or treated as indicated for NLRP3 (LPS+ATP) or pyrin (LPS+TcdB) inflammasome activation. (B and C) Release of IL-1b from peripheral blood mononuclear cells (PBMCs) (B) and the formation of ASC specks in monocytes (C) in CMML KRASmut patients at baseline or after the indicated stimulation or treatment (LPS+ATP and LPS+TcdB for NLRP3 or pyrin inflammasome, respectively), in the absence/presence of MCC950. (B) Fold increase was calculated to control non-stimulated conditions, where the average of the higher value used to calculate fold increase is 1,066.58 pg/mL. (D) Percentage of extracellular LDH from untreated PBMCs from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). Data are normalized to the percentage of monocytes. (E) Plasma concentration of HMGB1 <t>and</t> <t>P2X7</t> receptor from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). For (A)–(E), data are represented as mean ± SEM; each dot represents an individual patient; ordinary one-way ANOVA test (two-tailed) was used for (A) (* compares CMML KRASmut vs. healthy controls; y compares CMML KRASmut vs. CMML KRASwt), and two-tailed t test in (B)–(E). Note that * or yp < 0.05; **p < 0.01; ***p < 0.001; **** or yyyyp < 0.0001; ns, no significant difference (p > 0.05).
Apoptosis Elisa Kit, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/card+asc/Human+Apoptosis-associated+Speck-like+Protein+Containing+A+Card/10__3390_slash_molecules25071479-399-12-15
Average 90 stars, based on 1 article reviews
apoptosis elisa kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


MB inhibits pyroptosis in AMs caused by NLRP3 inflammasome in HCA rats. (A) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (B–F) Western blot bands and relative expression levels of NLRP3, caspase-1, pro-caspase-1, ASC, GSDMD-N, and GSDMD in AMs. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin-D.

Journal: Biomolecules and Biomedicine

Article Title: Methylene blue mitigates lung injury in HCA rats by regulating macrophage pyroptosis via Nrf2/HO-1 and NLRP3 pathways

doi: 10.17305/bb.2025.11851

Figure Lengend Snippet: MB inhibits pyroptosis in AMs caused by NLRP3 inflammasome in HCA rats. (A) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (B–F) Western blot bands and relative expression levels of NLRP3, caspase-1, pro-caspase-1, ASC, GSDMD-N, and GSDMD in AMs. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin-D.

Article Snippet: The samples were then subjected to electrophoresis on 12% SDS-PAGE gels (Invitrogen), transferred onto polyvinylidene difluoride (PVDF) membranes (Invitrogen), and blocked with 5% BSA for 3 h. After washing, the membranes were incubated overnight at 4 ∘ C with the following primary antibodies: Nrf2 (PA5-27882, 1:500, Invitrogen), HO-1 (PA5-77833, 1:1000, Invitrogen), NLRP3 (MA5-23919, 1:100, Invitrogen), pro-caspase-1 (ZRB1233, 1:1000, Sigma-Aldrich), caspase-1 (MA5-16215, 1:200, Invitrogen), ASC (HY- P80548 , 1:500, MedChemExpress), GSDMD-N (ab215203, 1:1000, Abcam), or GSDMD (PA5-116815, 1:1000, Invitrogen).

Techniques: Staining, Western Blot, Expressing

ML385 and Nigericin can partially restore MB to inhibit HCA-induced pyroptosis of rat lung macrophages and improve lung injury. (A–E) Western blot bands and relative levels of NLRP3, caspase-1, pro-caspase-1, ASC, GSDMD-N, and GSDMD in Ams; (F) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (G) Utilizing HE staining to evaluate the pathological changes in rat lung tissue, and to score lung injury (20×, bar ═ 100 µm); (H) The ROS level was measured utilizing DHE staining (20×, bar ═ 100 µm); (I–L) TNF-α, IL-6, ICAM-1, and IL-10 levels in BALF were assessed using ELISA kits. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; BALF: Bronchoalveolar lavage fluid; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; ROS: Reactive oxygen species; GSDMD: Gasdermin-D; ASC: Associated speck-like protein; HE: Hematoxylin and eosin; IL: Interleukin; DHE: Dihydroethidium.

Journal: Biomolecules and Biomedicine

Article Title: Methylene blue mitigates lung injury in HCA rats by regulating macrophage pyroptosis via Nrf2/HO-1 and NLRP3 pathways

doi: 10.17305/bb.2025.11851

Figure Lengend Snippet: ML385 and Nigericin can partially restore MB to inhibit HCA-induced pyroptosis of rat lung macrophages and improve lung injury. (A–E) Western blot bands and relative levels of NLRP3, caspase-1, pro-caspase-1, ASC, GSDMD-N, and GSDMD in Ams; (F) The pyroptosis level of rat AMs was detected by Yo-Pro-1 staining (green) and Hoechst 33342 staining (nuclear blue) (20×, bar ═ 100 µm); (G) Utilizing HE staining to evaluate the pathological changes in rat lung tissue, and to score lung injury (20×, bar ═ 100 µm); (H) The ROS level was measured utilizing DHE staining (20×, bar ═ 100 µm); (I–L) TNF-α, IL-6, ICAM-1, and IL-10 levels in BALF were assessed using ELISA kits. n ═ 6, * P < 0.05. MB: Methylene blue; HCA: Hypothermic circulatory arrest; BALF: Bronchoalveolar lavage fluid; AMs: Alveolar macrophages; NLRP3: Nod-like receptor protein 3; ROS: Reactive oxygen species; GSDMD: Gasdermin-D; ASC: Associated speck-like protein; HE: Hematoxylin and eosin; IL: Interleukin; DHE: Dihydroethidium.

Article Snippet: The samples were then subjected to electrophoresis on 12% SDS-PAGE gels (Invitrogen), transferred onto polyvinylidene difluoride (PVDF) membranes (Invitrogen), and blocked with 5% BSA for 3 h. After washing, the membranes were incubated overnight at 4 ∘ C with the following primary antibodies: Nrf2 (PA5-27882, 1:500, Invitrogen), HO-1 (PA5-77833, 1:1000, Invitrogen), NLRP3 (MA5-23919, 1:100, Invitrogen), pro-caspase-1 (ZRB1233, 1:1000, Sigma-Aldrich), caspase-1 (MA5-16215, 1:200, Invitrogen), ASC (HY- P80548 , 1:500, MedChemExpress), GSDMD-N (ab215203, 1:1000, Abcam), or GSDMD (PA5-116815, 1:1000, Invitrogen).

Techniques: Western Blot, Staining, Enzyme-linked Immunosorbent Assay

FIG. 4. Cryopyrin requires oligomerization for ASC binding and IL-1 secretion. A, schematic representation of the cryopyrinPD-Fpk3 or Fpk3 vector. B, 1 108 THP-1 cryopyrinPD-Fpk3 and Fpk3 stable cells were immunoprecipitated (IP) with polyclonal myc Ab (top panel), and total lysates (bottom panel) from stable cells were immunoblotted with monoclonal ASC Ab. C, 0.5 106 THP-1 cells stably expressing with cryopyrinPD-Fpk3 or Fpk3 vector in the presence () or absence () of Fpk3 ligand AP1510 for 0, 4, and 8 h followed by detection of IL-1 secretion. The results are given as the mean S.D. of triplicate cultures.

Journal: Journal of Biological Chemistry

Article Title: Cryopyrin-induced Interleukin 1β Secretion in Monocytic Cells

doi: 10.1074/jbc.m401178200

Figure Lengend Snippet: FIG. 4. Cryopyrin requires oligomerization for ASC binding and IL-1 secretion. A, schematic representation of the cryopyrinPD-Fpk3 or Fpk3 vector. B, 1 108 THP-1 cryopyrinPD-Fpk3 and Fpk3 stable cells were immunoprecipitated (IP) with polyclonal myc Ab (top panel), and total lysates (bottom panel) from stable cells were immunoblotted with monoclonal ASC Ab. C, 0.5 106 THP-1 cells stably expressing with cryopyrinPD-Fpk3 or Fpk3 vector in the presence () or absence () of Fpk3 ligand AP1510 for 0, 4, and 8 h followed by detection of IL-1 secretion. The results are given as the mean S.D. of triplicate cultures.

Article Snippet: The antibodies used for immunoprecipitation and immunodetection were anti-FLAG monoclonal (Santa Cruz), anti-Myc polyclonal (Santa Cruz), anti-ASC polyclonal ( ProSci), anti-ASC monoclonal (21), and anti-tubulin monoclonal (Sigma).

Techniques: Binding Assay, Plasmid Preparation, Immunoprecipitation, Stable Transfection, Expressing

Figure 3. Monocytes from CMML KRASmut patients present a constitutive inflammasome activation (A) Percentage of ASC-specking monocytes in healthy controls (white bars), CMML patients without KRAS mutation (KRASwt, blue bars), and CMML patients with a KRAS mutation (KRASmut, orange bars) at baseline or treated as indicated for NLRP3 (LPS+ATP) or pyrin (LPS+TcdB) inflammasome activation. (B and C) Release of IL-1b from peripheral blood mononuclear cells (PBMCs) (B) and the formation of ASC specks in monocytes (C) in CMML KRASmut patients at baseline or after the indicated stimulation or treatment (LPS+ATP and LPS+TcdB for NLRP3 or pyrin inflammasome, respectively), in the absence/presence of MCC950. (B) Fold increase was calculated to control non-stimulated conditions, where the average of the higher value used to calculate fold increase is 1,066.58 pg/mL. (D) Percentage of extracellular LDH from untreated PBMCs from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). Data are normalized to the percentage of monocytes. (E) Plasma concentration of HMGB1 and P2X7 receptor from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). For (A)–(E), data are represented as mean ± SEM; each dot represents an individual patient; ordinary one-way ANOVA test (two-tailed) was used for (A) (* compares CMML KRASmut vs. healthy controls; y compares CMML KRASmut vs. CMML KRASwt), and two-tailed t test in (B)–(E). Note that * or yp < 0.05; **p < 0.01; ***p < 0.001; **** or yyyyp < 0.0001; ns, no significant difference (p > 0.05).

Journal: Cell reports. Medicine

Article Title: NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.

doi: 10.1016/j.xcrm.2023.101329

Figure Lengend Snippet: Figure 3. Monocytes from CMML KRASmut patients present a constitutive inflammasome activation (A) Percentage of ASC-specking monocytes in healthy controls (white bars), CMML patients without KRAS mutation (KRASwt, blue bars), and CMML patients with a KRAS mutation (KRASmut, orange bars) at baseline or treated as indicated for NLRP3 (LPS+ATP) or pyrin (LPS+TcdB) inflammasome activation. (B and C) Release of IL-1b from peripheral blood mononuclear cells (PBMCs) (B) and the formation of ASC specks in monocytes (C) in CMML KRASmut patients at baseline or after the indicated stimulation or treatment (LPS+ATP and LPS+TcdB for NLRP3 or pyrin inflammasome, respectively), in the absence/presence of MCC950. (B) Fold increase was calculated to control non-stimulated conditions, where the average of the higher value used to calculate fold increase is 1,066.58 pg/mL. (D) Percentage of extracellular LDH from untreated PBMCs from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). Data are normalized to the percentage of monocytes. (E) Plasma concentration of HMGB1 and P2X7 receptor from healthy donors (white bar), KRASwt patients (blue bar), and KRASmut patients (orange bar). For (A)–(E), data are represented as mean ± SEM; each dot represents an individual patient; ordinary one-way ANOVA test (two-tailed) was used for (A) (* compares CMML KRASmut vs. healthy controls; y compares CMML KRASmut vs. CMML KRASwt), and two-tailed t test in (B)–(E). Note that * or yp < 0.05; **p < 0.01; ***p < 0.001; **** or yyyyp < 0.0001; ns, no significant difference (p > 0.05).

Article Snippet: Plasma or cell-free supernatants from fresh EDTA-anticoagulated PB samples from CMML patients and controls were used to quantify the concentration of human IL-1b (#BMS224INST, Invitrogen), human IL-18 (#7620, MBL), human IL-18BP (#EHIL18BP, Invitrogen), human TNF-a (#DTA00D, R&D Systems), human IL-6 (#D6050, R&D Systems), human ASC (#CSB-EL019114HU, Cusabio), human soluble P2X7 receptor (#CSB-EL017325HU, Cusabio), and human HMGB1 (#ARG81185, Arigo Biolaboratories) by ELISA following the manufacturer’s instructions.

Techniques: Activation Assay, Mutagenesis, Control, Clinical Proteomics, Concentration Assay, Two Tailed Test